Search research articles
Contact Us
Filters
Showing results (11-20 of 177) with videos related to
Page
of 18
Sort By:
Expert Opinion on Investigational Drugs
|
October 10, 2007
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies
Klaus Podar, Marc S Raab, Dharminder Chauhan, et al.
Haematologica
|
July 1, 2021
Novel immunotherapies in multiple myeloma - chances and challenges
Leo Rasche, Ralph Wäsch, Markus Munder, et al.
Hematological Oncology
|
August 26, 2017
Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach
Marc-Andrea Baertsch, Michael Hundemer, Jens Hillengass, et al.
Lancet (London, England)
|
June 23, 2009
Multiple myeloma
Marc S Raab, Klaus Podar, Iris Breitkreutz, et al.
Ejhaem
|
November 29, 2023
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
Marc S Raab, Elena Zamagni, Salomon Manier, et al.
Blood
|
February 18, 2016
Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition
Marc S Raab, Nicola Lehners, Jing Xu, et al.
Hematological Oncology
|
July 8, 2017
Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice
Marc-Andrea Baertsch, Jens Hillengass, Joanna Blocka, et al.
Annals of Hematology
|
January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma
Iris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Journal of Medicinal Chemistry
|
December 24, 2011
Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells
Mads H Rønnest, Marc S Raab, Simon Anderhub, et al.
Leukemia & Lymphoma
|
April 5, 2018
Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders
Nicola Lehners, Elena Ellert, Jing Xu, et al.
Page
of 18
Search research articles
Search
Showing results (11-20 of 177) with videos related to
Sort By:
Page
of 18
Expert Opinion on Investigational Drugs
|
October 10, 2007
The therapeutic role of targeting protein kinase C in solid and hematologic malignancies
Klaus Podar, Marc S Raab, Dharminder Chauhan, et al.
Haematologica
|
July 1, 2021
Novel immunotherapies in multiple myeloma - chances and challenges
Leo Rasche, Ralph Wäsch, Markus Munder, et al.
Hematological Oncology
|
August 26, 2017
Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach
Marc-Andrea Baertsch, Michael Hundemer, Jens Hillengass, et al.
Lancet (London, England)
|
June 23, 2009
Multiple myeloma
Marc S Raab, Klaus Podar, Iris Breitkreutz, et al.
Ejhaem
|
November 29, 2023
Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
Marc S Raab, Elena Zamagni, Salomon Manier, et al.
Blood
|
February 18, 2016
Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition
Marc S Raab, Nicola Lehners, Jing Xu, et al.
Hematological Oncology
|
July 8, 2017
Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice
Marc-Andrea Baertsch, Jens Hillengass, Joanna Blocka, et al.
Annals of Hematology
|
January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma
Iris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Journal of Medicinal Chemistry
|
December 24, 2011
Disparate SAR data of griseofulvin analogues for the dermatophytes Trichophyton mentagrophytes, T. rubrum, and MDA-MB-231 cancer cells
Mads H Rønnest, Marc S Raab, Simon Anderhub, et al.
Leukemia & Lymphoma
|
April 5, 2018
Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders
Nicola Lehners, Elena Ellert, Jing Xu, et al.
Page
of 18